0.3029
Precedente Chiudi:
$0.3061
Aprire:
$0.3084
Volume 24 ore:
2.35M
Relative Volume:
0.43
Capitalizzazione di mercato:
$37.75M
Reddito:
$36.86M
Utile/perdita netta:
$-171.67M
Rapporto P/E:
-0.2019
EPS:
-1.5
Flusso di cassa netto:
$-171.05M
1 W Prestazione:
-20.18%
1M Prestazione:
-40.41%
6M Prestazione:
-85.71%
1 anno Prestazione:
-92.87%
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Nome
Mersana Therapeutics Inc
Settore
Industria
Telefono
617-498-0020
Indirizzo
840 MEMORIAL DRIVE, CAMBRIDGE
Confronta MRSN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
MRSN
Mersana Therapeutics Inc
|
0.3029 | 37.75M | 36.86M | -171.67M | -171.05M | -1.50 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-06 | Iniziato | William Blair | Outperform |
2024-11-15 | Ripresa | Citigroup | Buy |
2024-03-19 | Aggiornamento | JP Morgan | Underweight → Neutral |
2024-02-29 | Aggiornamento | BTIG Research | Neutral → Buy |
2024-02-29 | Aggiornamento | Guggenheim | Neutral → Buy |
2024-02-29 | Aggiornamento | Wedbush | Neutral → Outperform |
2023-12-04 | Aggiornamento | Citigroup | Neutral → Buy |
2023-07-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
2023-07-27 | Downgrade | BTIG Research | Buy → Neutral |
2023-07-27 | Downgrade | Citigroup | Buy → Neutral |
2023-07-27 | Downgrade | Guggenheim | Buy → Neutral |
2023-07-27 | Downgrade | JP Morgan | Neutral → Underweight |
2023-07-27 | Downgrade | Truist | Buy → Hold |
2023-07-27 | Downgrade | Wedbush | Outperform → Neutral |
2023-06-16 | Downgrade | JP Morgan | Overweight → Neutral |
2023-06-15 | Iniziato | Guggenheim | Buy |
2023-03-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
2023-01-20 | Iniziato | Citigroup | Buy |
2022-11-21 | Iniziato | Truist | Buy |
2021-10-15 | Ripresa | BTIG Research | Buy |
2021-08-30 | Iniziato | H.C. Wainwright | Buy |
2021-03-31 | Iniziato | Credit Suisse | Neutral |
2020-12-03 | Iniziato | Stifel | Buy |
2020-09-29 | Ripresa | JP Morgan | Neutral |
2020-04-29 | Iniziato | BTIG Research | Buy |
2020-01-21 | Reiterato | H.C. Wainwright | Buy |
2019-03-11 | Downgrade | JP Morgan | Neutral → Underweight |
2018-11-14 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
2018-05-08 | Iniziato | Robert W. Baird | Outperform |
2018-03-19 | Downgrade | JP Morgan | Overweight → Neutral |
Mostra tutto
Mersana Therapeutics Inc Borsa (MRSN) Ultime notizie
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Mersana Strengthens Team with Strategic 26,790-Share RSU Grant to New Hire - Stock Titan
When Would Be The Best Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - stocksregister.com
Mersana Therapeutics Announces Upcoming Oral Presentation - GlobeNewswire
FDA Fast-Tracked Breast Cancer Drug Shows Promise: Key Clinical Data Coming at ESMO 2025 - Stock Titan
Critical Contrast: Mersana Therapeutics (NASDAQ:MRSN) & Opus Genetics (NASDAQ:IRD) - Defense World
MRSN stock plunges to 52-week low of $0.37 amid market challenges - Investing.com India
MRSN stock plunges to 52-week low of $0.37 amid market challenges By Investing.com - Investing.com South Africa
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough - simplywall.st
MRSN stock touches 52-week low at $0.43 amid sharp decline - Investing.com India
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
MRSN stock plunges to 52-week low of $0.45 amid market challenges - Investing.com Australia
Mersana at Leerink Global Healthcare Conference: Strategic ADC Insights By Investing.com - Investing.com Canada
MRSN stock plunges to 52-week low of $0.45 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimates for Mersana Therapeutics Lowered by Wedbush - MarketBeat
Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Simply Wall St
Mersana Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Brokers Issue Forecasts for MRSN Q1 Earnings - Defense World
Q1 EPS Estimate for Mersana Therapeutics Reduced by Analyst - Defense World
Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance
Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts - Yahoo Finance
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates - MSN
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call Transcript - Insider Monkey
Mersana Therapeutics (NASDAQ:MRSN) Receives “Outperform” Rating from Wedbush - Defense World
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Mersana Therapeutics’ Viability in Question Amidst Persistent Financial Losses and Funding Challenges - TipRanks
Mersana Therapeutics Reports Progress and Financial Results - TipRanks
Mersana Therapeutics’ Earnings Call Highlights Clinical Progress and Financial Gains - TipRanks
Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast By Investing.com - Investing.com Canada
Earnings call transcript: Mersana Therapeutics Q4 2024 beats EPS forecast - Investing.com India
Mersana Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Mersana Therapeutics reports Q4 EPS (11c), consensus (17c) - TipRanks
Mersana Therapeutics, Inc. SEC 10-K Report - TradingView
Mersana Therapeutics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Mersana Therapeutics Announces Positive Phase 1 Clinical Data - TipRanks
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Mersana's ADC Pipeline Advances: FDA Fast Track Designation as Q4 Losses Narrow - StockTitan
What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings - GuruFocus.com
MRSN stock touches 52-week low at $0.49 amid sharp annual decline - Investing.com Australia
William Blair starts Mersana stock with Outperform rating - MSN
Mersana Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa
Mersana Therapeutics faces Nasdaq delisting over share price - Investing.com
MRSN stock touches 52-week low at $0.49 amid sharp annual decline By Investing.com - Investing.com South Africa
Mersana Therapeutics Inc Azioni (MRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):